BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Marine Polymer Technologies Announces Positive Results of Talymed(TM) Clinical Trial Published in the Journal of the American Academy of Dermatology


6/23/2011 6:53:29 AM

DANVERS, Mass.--(BUSINESS WIRE)-- Marine Polymer Technologies, Inc. today announced that positive clinical trial results of Talymed, an advanced bio-active wound-healing technology, for the treatment of patients with hard-to-heal venous leg ulcers (VLUs) were published in the Journal of the American Academy Dermatology. The study compared the proportion of patients who achieved complete wound healing at 20 weeks using Talymed plus standard care versus those who received standard care alone. Study investigators reported that nearly twice as many patients who received biweekly Talymed in addition to standard care achieved complete wound healing at 20 weeks, compared to patients who received standard care alone (86.4% versus 45.0%, p<0.01). An abstract of the published article entitled, “A randomized, investigator-blinded, controlled pilot study to evaluate the safety and efficacy of a poly-N-acetyl glucosamine-derived membrane material in patients with venous leg ulcers,” is available at the journal’s website at http://www.eblue.org/article/S0190-9622(11)00303-3/abstract.

The newly published study enrolled adult patients with VLUs who sought treatment at wound care clinics. The primary endpoint, the proportion of patients who achieved complete VLU healing at 20 weeks, compared healing rates of patients who received Talymed in addition to standard care to those of patients who received standard care alone. Data obtained from all randomized patients were included in the analysis (intent-to-treat analysis). At enrollment into the study, the average patient age was 61.5 years, average ulcer size was 11.2 cm2, mean VLU duration was 3 months, and the most common comorbid conditions were hypertension (74%), diabetes (61%), arthritis (46%), class III obesity (45%), and blood clotting disorders (23%). At 20 weeks, 86.4% of patients who received Talymed every other week (10 applications) achieved complete healing, versus 45.0% of patients who received standard care alone; findings were highly statistically significant (p<0.01). No significant treatment-related adverse events or reactions occurred during the study and none of the subjects experienced increased pain or edema.

“VLUs, which affect more than a half a million people in the US, are very challenging and potentially serious wounds that are caused, in part, by poor venous circulation” said Teresa Kelechi, PhD, lead investigator and Chair, College of Nursing at the Medical University of South Carolina. “Patients with VLUs often experience considerable pain and swelling, poor functioning and quality of life, and are at risk for developing dangerous wound site and systemic infections. These wounds are notoriously difficult to heal. After 20 weeks of treatment with standard care, which consists of compression bandaging and moist dressings, only about half of VLUs are usually completely healed. We were therefore surprised to find that at 20 weeks, the proportion of patients who achieved complete healing with the bi-weekly addition of Talymed was nearly double that of patients who received standard care alone. By virtue of its significant wound healing benefits, Talymed may also decrease the risk for infection, improve patient functioning and well-being, and ultimately reduce health care costs.”

About Talymed

Talymed is a bio-active matrix that is cleared by the US Food and Drug Administration (FDA) for the management of wounds, including diabetic ulcers, venous ulcers, pressure ulcers, ulcers of mixed vascular causes, partial- and full-thickness wounds, second-degree burns, surgical wounds, and other bleeding surface wounds and abrasions. The active ingredient in Talymed is poly-N-acetyl glucosamine (pGlcNAc),nanofiber technology. The mechanism of action of pGlcNAc nanofiber-based matrix has been investigated in vitro and in vivo. Increased wound-healing rates may occur in response to enhanced angiogenesis and granulation tissue formation, in concert with rapid epithelialization.

About Marine Polymer Technologies, Inc.

Marine Polymer Technologies (MPT) is a privately-held medical device company that researches, develops and markets technologies for patient hemostasis and wound healing based on a proprietary microalgae-based polymer. In addition to Talymed, MPT products include Syvek Excel® Vascular Access Hemostasis System for use following femoral catheterization procedures to assist in obtaining and maintaining hemostasis; the Syvek® NT for use in the local management of bleeding wounds such as vascular access sites, percutaneous catheters or tubes and surgical debridement; and the MRDH™ trauma dressing intended for the temporary control of severely bleeding wounds such as surgical wounds (operative, post-operative, donor sites, dermatological, etc.) and traumatic injuries.

Contact:

Marine Polymer TechnologiesSergio Finkielsztein, +1 781-270-3200President and CEO



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES